May 26 (Reuters) - Bioblast Pharma Ltd :Bioblast pharma reports first quarter 2017 financial results.Q1 loss per share $0.16.Bioblast pharma ltd says pre-commercial expenses were $0.4 million for quarter ended march 31, 2017, compared to $0.8 million for same period in 2016.Bioblast pharma ltd - qtrly loss per share $0.16.Bioblast pharma- cash, cash equivalents and short-term bank deposits as of march 31, 2017, were $7.1 million, compared to $9.9 million as of december 31, 2016.Bioblast pharma ltd - "should we be unable to obtain additional funding required to continue our clinical activity".Bioblast pharma ltd - "we may need to reduce our activities and to explore strategic alternatives until we have sufficient resources".Bioblast pharma ltd - additional funding beyond existing cash resources will be required to entirely cover cost of phase 2b clinical study.
May 22 (Reuters) - Glycomimetics Inc :Glycomimetics announces proposed public offering of common stock.Intends to offer and sell, subject to market conditions, 6 million shares of common stock in an underwritten public offering.To use net proceeds to complete its ongoing phase 1/2 clinical trial of GMI-1271 in patients with acute myeloid leukemia (AML).Also intends to use net proceeds to complete its ongoing phase 1 clinical trial of GMI-1271 in patients with multiple myeloma (MM).
May 18 (Reuters) - Obseva SA :Obseva reports first quarter 2017 financial results and business update.Q1 loss per share $0.58.Obseva SA - as of March 31, 2017, Obseva had cash and cash equivalents of $104.2 million.Obseva SA - research and development expenses were $13.1 million and general and administrative expenses were $2.7 million for quarter ended March 31, 2017.
May 15 (Reuters) - Immunocellular Therapeutics Ltd ::Immunocellular Therapeutics announces first quarter 2017 financial results.Q1 loss per share $1.64.Immunocellular Therapeutics Ltd - Company considering potential strategic alternatives for ICT-107.Immunocellular Therapeutics Ltd - in light of uncertainties surrounding strategic pursuits, company is deferring a Business Update Conference Call.Immunocellular Therapeutics - also intends to evaluate strategies to refocus and reallocate resources on stem-To-T-Cell Research Programs.
May 15 (Reuters) - Windtree Therapeutics Inc :Windtree Therapeutics reports first quarter 2017 financial results and provides key business updates.For quarter ended march 31, 2017, company reported an operating loss of $8.1 million, compared to $13.9 million for Q1 of 2016.Grant revenue for Q1 of 2017 was $0.2 million compared to $0.1 million for Q1 of 2016.Anticipates that it has sufficient cash to support operations through planned completion of aerosurf phase 2b clinical trial.
May 15 (Reuters) - Ampliphi Biosciences Corp :Ampliphi Biosciences reports first quarter 2017 financial results and provides business highlights.Q1 loss per share $1.94.Ampliphi Biosciences Corp - Cash and cash equivalents were $2.2 million as of March 31, 2017, compared with $5.7 million as of December 31, 2016.Ampliphi Biosciences Corp - Ampliphi recorded a gain for Q1 of 2017 of $114,000 related to change in fair value of derivative liabilities.
May 15 (Reuters) - Bellerophon Therapeutics Inc ::Bellerophon reports first quarter 2017 financial results and provides business update.Q1 loss per share $0.60.Bellerophon Therapeutics - believes that as of march 31, 2017, it has sufficient funds to satisfy its operating cash needs for at least next 12 months.Bellerophon Therapeutics - at March 31, 2017, co had cash and cash equivalents, restricted cash and marketable securities of $17.1 million compared to $20.5 million at December 31, 2016.
May 12 (Reuters) - Celsion Corp -:Celsion Corporation reports first quarter 2017 financial results and provides business update.Q1 loss share per $0.12.Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.Celsion Corp - research and development costs were relatively constant at $3.5 million and $3.4 million in first quarters of 2017 and 2016, respectively.Celsion Corp - plans to activate 5 additional clinical trial sites in vietnam by q2 of 2017 for optima study.Celsion Corp - company ended q1 of 2017 with $4.5 million of total cash and cash equivalents.
May 12 (Reuters) - PROBIODRUG AG ::PROBIODRUG AG REPORTS FIRST QUARTER 2017 BUSINESS UPDATE.Q1 OF 2017 SHOWED AN INCREASE OF RESEARCH AND DEVELOPMENT EXPENSES TO EUR 2,268K COMPARED TO EUR 1,974K IN Q1 OF 2016.Q1 COMPREHENSIVE LOSS OF THE REPORTING PERIOD WAS EUR 2,798K, COMPARED TO EUR 2,596K IN THE FIRST QUARTER OF 2016.PROBIODRUG HELD EUR 18.7 MILLION IN CASH AND CASH EQUIVALENTS AS OF 31 MARCH 2017.
May 11 (Reuters) - Auris Medical Holding Ag : :Auris Medical provides business update and reports first quarter 2017 financial results.Q1 loss per share chf 0.22.Auris Medical Holding AG - net loss for q1 of 2017 was chf 8.4 million, or chf 0.22 per share.Auris Medical Holding AG - continues to expect that its operating expenses in 2017 will be in range of chf 28 to 32 million.Auris Medical Holding AG - continues to expect existing cash and cash equivalents will enable funding of operations into q1 of 2018.